These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35431057)

  • 1. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
    Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
    Actas Dermosifiliogr; 2022 Jun; 113(6):610-615. PubMed ID: 35431057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
    Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
    Actas Dermosifiliogr; 2022 Jun; 113(6):T610-T615. PubMed ID: 35525283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma.
    Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K
    Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
    Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
    Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
    Migden MR; Khushalani NI; Chang ALS; Lewis KD; Schmults CD; Hernandez-Aya L; Meier F; Schadendorf D; Guminski A; Hauschild A; Wong DJ; Daniels GA; Berking C; Jankovic V; Stankevich E; Booth J; Li S; Weinreich DM; Yancopoulos GD; Lowy I; Fury MG; Rischin D
    Lancet Oncol; 2020 Feb; 21(2):294-305. PubMed ID: 31952975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma.
    De Falco V; Napolitano S; Franco R; Zito Marino F; Formisano L; Esposito D; Suarato G; Napolitano R; Esposito A; Caraglia F; Giugliano MC; Cioli E; Famiglietti V; Bianco R; Argenziano G; Ronchi A; Ciardiello D; Nardone V; D'Ippolito E; Del Tufo S; Ciardiello F; Troiani T
    Oncoimmunology; 2024; 13(1):2388315. PubMed ID: 39206096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
    Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG
    N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Locally advanced and metastatic cutaneous squamous cell carcinoma treated with cemiplimab].
    Vanhakendover L; Lebas E; Libon F; Wauters O; Dezfoulian B; Marchal N; Rorive A; Piret P; Quatresooz P; Jacquemin D; Nikkels AF
    Rev Med Liege; 2019 Jul; 74(7-8):436-440. PubMed ID: 31373461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
    Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E
    Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel.
    Lebas E; Marchal N; Rorive A; Nikkels AF
    Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis.
    Nardone V; Napolitano S; Gagliardi F; Esposito A; Caraglia F; Briatico G; Scharf C; Ronchi A; D'Onofrio I; D'Ippolito E; Russo A; Belfiore MP; Franco R; Argenziano G; Ciardiello F; Reginelli A; Cappabianca S; Troiani T
    J Am Acad Dermatol; 2024 Oct; 91(4):678-683. PubMed ID: 38885840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
    Swanson L; Kassab I; Tsung I; Worden FP; Fontana RJ
    Immunotherapy; 2022 Apr; 14(6):409-418. PubMed ID: 35232282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios.
    Akhtar K; Sravanthi MV; D'Angelo J; Sivapiragasam A
    J Investig Med High Impact Case Rep; 2022; 10():23247096221121408. PubMed ID: 36017984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma-A Retrospective Single-Center Study.
    Kuzmanovszki D; Kiss N; Tóth B; Tóth V; Szakonyi J; Lőrincz K; Hársing J; Kuroli E; Imrédi E; Kerner T; Patyánik M; Wikonkál NM; Szabó Á; Brodszky V; Rencz F; Holló P
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cemiplimab in advanced cutaneous squamous cell carcinoma.
    Naik PP
    Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab-Real-World Experience in the Global SARS-CoV-2 Pandemic.
    Pabianek M; Lesiak A; Nejc D; Kuncman Ł; Narbutt J; Skibińska M; Ciążyńska M
    Curr Oncol; 2022 Oct; 29(10):7794-7801. PubMed ID: 36290893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
    Rischin D; Hughes BGM; Basset-Séguin N; Schadendorf D; Bowyer S; Trabelsi Messai S; Meier F; Eigentler TK; Casado Echarren V; Stein B; Beylot-Barry M; Dalac S; Dréno B; Migden MR; Hauschild A; Schmults CD; Lim AM; Yoo SY; Paccaly AJ; Papachristos A; Nguyen JH; Okoye E; Seebach F; Booth J; Lowy I; Fury MG; Guminski A
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
    Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
    Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.
    Hughes BGM; Guminski A; Bowyer S; Migden MR; Schmults CD; Khushalani NI; Chang ALS; Grob JJ; Lewis KD; Ansstas G; Day F; Ladwa R; Stein BN; Muñoz Couselo E; Meier F; Hauschild A; Schadendorf D; Basset-Seguin N; Modi B; Dalac-Rat S; Dunn LA; Flatz L; Mortier L; Guégan S; Heinzerling LM; Mehnert JM; Trabelsi S; Soria-Rivas A; Stratigos AJ; Ulrich C; Wong DJ; Beylot-Barry M; Bossi P; Bugés Sánchez C; Chandra S; Robert C; Russell JS; Silk AW; Booth J; Yoo SY; Seebach F; Lowy I; Fury MG; Rischin D
    J Am Acad Dermatol; 2025 Jan; 92(1):68-77. PubMed ID: 39245360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.
    Rischin D; Khushalani NI; Schmults CD; Guminski A; Chang ALS; Lewis KD; Lim AM; Hernandez-Aya L; Hughes BGM; Schadendorf D; Hauschild A; Thai AA; Stankevich E; Booth J; Yoo SY; Li S; Chen Z; Okoye E; Chen CI; Mastey V; Sasane M; Lowy I; Fury MG; Migden MR
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34413166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.